Long-Term Anticoagulant Therapy In Atrial Fibrillation: Dabigatran Vs. Warfarin
Links shared publicly online about this topic.
- 1,781total visits
Long-Term Anticoagulant Therapy In Atrial Fibrillation: Dabigatran Vs. Warfarin
View full resource at medicalnewstoday.com
Tags: Heart Disease, Arrhythmia, Atrial Fibrillation, Stroke, Anti-Clotting Medication, Anticoagulant, Coumadin
Most Recently Shared on September 1, 2009 at 2:52 pm By:
Long-Term Anticoagulant Therapy In Atrial Fibrillation: Dabigatran Vs. Warfarin: The anticoagulant dabigatran is.. http://bit.ly/c8akZ
ESC | Congresses | ESC Congress 2011 | RE-LY: Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY®) trial
escardio.org — “Congress report, ESC congress 2011,Clinical Trial Update I - Drug treatment,Atrial fibrillation (AF)” View full resource at escardio.org
Most Recently Shared on August 28, 2011 at 3:25 pm By:
Michael Katz Doctor, Internist, and Physician
Superiority of 150 mg dose of dabigatran disappears when clopidogrel added. http://ow.ly/6eQtU #escparis2011
New era for anticoagulant therapy
news-medical.net — “In a Guest Editorial published in the new publication Clinical Investigation, Dr Jeffrey Weitz and Dr John Eikelboom of McMaster University in Hamilton, Canada highlight the importance of the approval in October by the FDA of dabigatran etexilate (Pradaxa®; Boehringer Ingelheim). This new oral thrombin inhibitor provides an alternative to warfarin for long-term stroke prevention in patients with non-valvular atrial fibrillation.” View full resource at news-medical.net
Most Recently Shared on December 23, 2010 at 12:45 am By:
Stroke News: New era for anticoagulant therapy: In a Guest Editorial published in the new publication Clinical... http://twurl.nl/iei23e
RE-LY Trial Met Primary Outcome For Reducing Incidence Of Stroke Or Systemic Embolism In Non-valvular Atrial Fibrillation Patients
medicalnewstoday.com — “Boehringer ingelheim announced that results from the re-ly(r) (randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran) study -- the largest atrial fibrillatio” View full resource at medicalnewstoday.com
Most Recently Shared on September 1, 2009 at 12:20 pm By:
MedicalNewsToday: RE-LY Trial Met Primary Outcome For Reducing Incidence Of Stroke Or Systemic http://bit.ly/YwMS9 Full http://bit.ly/7D6yK
Phase III RE-LY study results to be presented at the European Society of Cardiology Congress
news-medical.net — “Results of the Phase III RE-LY(R) (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF” View full resource at news-medical.net
Most Recently Shared on August 26, 2009 at 8:01 am By:
Stroke News: Phase III RE-LY study results to be presented at the European Society of Cardiology Con.. http://twurl.nl/madfox
Advertisement
